8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Jul 17, 2006)

Filed July 17, 2006For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an 8-K on July 17, 2006, to report a significant reclassification of its financial statements. The company has elected to present its Consumer Healthcare business as a "Discontinued Operation" in its consolidated statements of income for both the full year 2005 and the first quarter of 2006. This change in presentation will allow investors to better distinguish the ongoing performance of Pfizer's core pharmaceutical operations from the results of the divested or soon-to-be-divested Consumer Healthcare segment. The reclassification is effective retroactively for the periods presented, meaning comparative financial results will reflect this change. This move is often a precursor to a sale or spin-off of the business segment being classified as discontinued. Investors should pay close attention to the details within the press release attached as Exhibit 99 for a clearer understanding of the financial impact and Pfizer's strategic rationale behind this presentation change.

Key Highlights

  • 1Pfizer is reclassifying its Consumer Healthcare business as a Discontinued Operation.
  • 2This reclassification impacts the consolidated statements of income for full year 2005 and Q1 2006.
  • 3The change is presented retroactively for comparative purposes.
  • 4This accounting treatment typically signals a potential divestiture or spin-off of the business segment.
  • 5The press release containing these reclassified statements is filed as Exhibit 99 to the 8-K.
  • 6Investors can now better assess the performance of Pfizer's core ongoing operations.

Frequently Asked Questions

Pfizer is reclassifying its Consumer Healthcare business to "Discontinued Operation" to provide a clearer view of its ongoing core pharmaceutical business performance. This accounting treatment separates the financial results of the Consumer Healthcare segment from its continuing operations, making it easier for investors to analyze the core business's profitability and trends.

The reclassification affects Pfizer's consolidated statements of income for the full year 2005 and the first quarter of 2006. The company has provided reclassified statements for these periods to reflect the Consumer Healthcare business as discontinued.

While not explicitly stated as a sale in the 8-K filing itself, classifying a business segment as a "Discontinued Operation" is a common accounting step taken when a company intends to divest or has already divested that segment. It signals a significant change in Pfizer's strategic direction regarding its Consumer Healthcare assets.

More details about this reclassification, including the specific financial figures and Pfizer's rationale, can be found in the press release dated July 17, 2006, which is attached as Exhibit 99 to this 8-K filing.